NCT06184282

Brief Summary

This study aims to assess topical MEBO application on pain relief and wound healing.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
28

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jul 2023

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2023

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2023

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

December 14, 2023

Completed
14 days until next milestone

First Posted

Study publicly available on registry

December 28, 2023

Completed
Last Updated

January 3, 2024

Status Verified

December 1, 2023

Enrollment Period

1 month

First QC Date

December 14, 2023

Last Update Submit

December 28, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • The degree of pain

    Pain score was reported by the patient directly through Visual Analogue Scale (VAS) score (between 0 and 10; 0: no pain, 1:minimal pain, 5: moderate pain, and 10: severe pain) VAS was recorded daily for 1 week.

    10 days after surgery

Secondary Outcomes (3)

  • Wound Size

    10 days after surgery

  • The degree of re-epithelization

    10 days after surgery

  • The degree of keratinization

    10 days after surgery

Study Arms (2)

MEBO group

EXPERIMENTAL

MEBO (Julphar®, Ras Al Khaimah, United Arab Emirates) was applied using sterile plastic brush daily and the patients were recalled at 2, 5 and 10 days for evaluating the healing of the ulcer.

Drug: MEBO

Control Group

ACTIVE COMPARATOR

Lidocaine gel was applied using sterile plastic brush daily and the patients were recalled at 2, 5 and 10 days for evaluating the healing of the ulcer.

Drug: Lidocaine

Interventions

MEBODRUG

MEBO (Julphar®, Ras Al Khaimah, United Arab Emirates) was applied using sterile plastic brush daily and the patients were recalled at 2, 5 and 10 days for evaluating the healing of the ulcer.

MEBO group

Lidocaine gel was applied using sterile plastic brush daily and the patients were recalled at 2, 5 and 10 days for evaluating the healing of the ulcer.

Control Group

Eligibility Criteria

Age20 Years - 50 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Age from 20 to 50 years.
  • Both sexes.
  • Systemically healthy patients.
  • Patients with good oral hygiene.

You may not qualify if:

  • Patients with any uncontrolled local or systemic disease.
  • Smokers.
  • Pregnancy and lactation.
  • Patients allergic to the used agents.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

October 6 University

Giza, 12511, Egypt

Location

MeSH Terms

Interventions

Lidocaine

Intervention Hierarchy (Ancestors)

AcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer of Oral Medicine, Diagnosis and Periodontology, Faculty of Dentistry, October 6 University, 6 October city, Egypt

Study Record Dates

First Submitted

December 14, 2023

First Posted

December 28, 2023

Study Start

July 1, 2023

Primary Completion

August 1, 2023

Study Completion

August 1, 2023

Last Updated

January 3, 2024

Record last verified: 2023-12

Data Sharing

IPD Sharing
Will share

The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Shared Documents
STUDY PROTOCOL
Time Frame
After the end of study for one year.
Access Criteria
The data will be available upon a reasonable request from the corresponding author.

Locations